Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Identifieur interne : 000200 ( PubMed/Curation ); précédent : 000199; suivant : 000201Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Auteurs : P J Peters [États-Unis] ; J. Stringer ; M S Mcconnell ; J. Kiarie ; W. Ratanasuwan ; P. Intalapaporn ; D. Potter ; W. Mutsotso ; I. Zulu ; C B Borkowf ; O. Bolu ; J T Brooks ; P J WeidleSource :
- HIV medicine [ 1468-1293 ] ; 2010.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Alanine transaminase (sang), Aspartate aminotransferases (sang), Association de médicaments, Exanthème (), Exanthème (épidémiologie), Femelle, Humains, Hypersensibilité médicamenteuse (épidémiologie), Hypersensibilité médicamenteuse (étiologie), Indice de gravité médicale, Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Inhibiteurs de la transcriptase inverse (administration et posologie), Inhibiteurs de la transcriptase inverse (effets indésirables), Jeune adulte, Kenya, Lésions hépatiques dues aux substances (sang), Lésions hépatiques dues aux substances (épidémiologie), Lésions hépatiques dues aux substances (étiologie), Méthodes épidémiologiques, Numération des lymphocytes CD4, Névirapine (administration et posologie), Névirapine (effets indésirables), Thaïlande, Toxidermies (épidémiologie), Zambie.
- MESH :
- administration et posologie : Inhibiteurs de la transcriptase inverse, Névirapine.
- effets indésirables : Inhibiteurs de la transcriptase inverse, Névirapine.
- immunologie : Infections à VIH.
- sang : Alanine transaminase, Aspartate aminotransferases, Lésions hépatiques dues aux substances.
- traitement médicamenteux : Infections à VIH.
- épidémiologie : Exanthème, Hypersensibilité médicamenteuse, Lésions hépatiques dues aux substances, Toxidermies.
- étiologie : Hypersensibilité médicamenteuse, Lésions hépatiques dues aux substances.
- Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Exanthème, Femelle, Humains, Indice de gravité médicale, Jeune adulte, Kenya, Méthodes épidémiologiques, Numération des lymphocytes CD4, Thaïlande, Zambie.
English descriptors
- KwdEn :
- Adolescent, Adult, Alanine Transaminase (blood), Aspartate Aminotransferases (blood), CD4 Lymphocyte Count, Chemical and Drug Induced Liver Injury (blood), Chemical and Drug Induced Liver Injury (epidemiology), Chemical and Drug Induced Liver Injury (etiology), Drug Eruptions (epidemiology), Drug Hypersensitivity (epidemiology), Drug Hypersensitivity (etiology), Drug Therapy, Combination, Epidemiologic Methods, Exanthema (chemically induced), Exanthema (epidemiology), Female, HIV Infections (drug therapy), HIV Infections (immunology), Humans, Kenya, Middle Aged, Nevirapine (administration & dosage), Nevirapine (adverse effects), Reverse Transcriptase Inhibitors (administration & dosage), Reverse Transcriptase Inhibitors (adverse effects), Severity of Illness Index, Thailand, Young Adult, Zambia.
- MESH :
- chemical , administration & dosage : Nevirapine, Reverse Transcriptase Inhibitors.
- chemical , adverse effects : Nevirapine, Reverse Transcriptase Inhibitors.
- chemical , blood : Alanine Transaminase, Aspartate Aminotransferases.
- blood : Chemical and Drug Induced Liver Injury.
- chemically induced : Exanthema.
- drug therapy : HIV Infections.
- epidemiology : Chemical and Drug Induced Liver Injury, Drug Eruptions, Drug Hypersensitivity, Exanthema.
- etiology : Chemical and Drug Induced Liver Injury, Drug Hypersensitivity.
- immunology : HIV Infections.
- Adolescent, Adult, CD4 Lymphocyte Count, Drug Therapy, Combination, Epidemiologic Methods, Female, Humans, Kenya, Middle Aged, Severity of Illness Index, Thailand, Young Adult, Zambia.
Abstract
The aim of the study was to determine risk factors for developing severe hepatotoxicity (grade 3 or 4 hepatotoxicity) and rash-associated hepatotoxicity (rash with ≥ grade 2 hepatotoxicity) among women initiating nevirapine-based antiretroviral therapy (ART).
DOI: 10.1111/j.1468-1293.2010.00873.x
PubMed: 20659176
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000200
Links to Exploration step
pubmed:20659176Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.</title><author><name sortKey="Peters, P J" sort="Peters, P J" uniqKey="Peters P" first="P J" last="Peters">P J Peters</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pjpeters@cdc.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA 30333</wicri:regionArea></affiliation></author><author><name sortKey="Stringer, J" sort="Stringer, J" uniqKey="Stringer J" first="J" last="Stringer">J. Stringer</name></author><author><name sortKey="Mcconnell, M S" sort="Mcconnell, M S" uniqKey="Mcconnell M" first="M S" last="Mcconnell">M S Mcconnell</name></author><author><name sortKey="Kiarie, J" sort="Kiarie, J" uniqKey="Kiarie J" first="J" last="Kiarie">J. Kiarie</name></author><author><name sortKey="Ratanasuwan, W" sort="Ratanasuwan, W" uniqKey="Ratanasuwan W" first="W" last="Ratanasuwan">W. Ratanasuwan</name></author><author><name sortKey="Intalapaporn, P" sort="Intalapaporn, P" uniqKey="Intalapaporn P" first="P" last="Intalapaporn">P. Intalapaporn</name></author><author><name sortKey="Potter, D" sort="Potter, D" uniqKey="Potter D" first="D" last="Potter">D. Potter</name></author><author><name sortKey="Mutsotso, W" sort="Mutsotso, W" uniqKey="Mutsotso W" first="W" last="Mutsotso">W. Mutsotso</name></author><author><name sortKey="Zulu, I" sort="Zulu, I" uniqKey="Zulu I" first="I" last="Zulu">I. Zulu</name></author><author><name sortKey="Borkowf, C B" sort="Borkowf, C B" uniqKey="Borkowf C" first="C B" last="Borkowf">C B Borkowf</name></author><author><name sortKey="Bolu, O" sort="Bolu, O" uniqKey="Bolu O" first="O" last="Bolu">O. Bolu</name></author><author><name sortKey="Brooks, J T" sort="Brooks, J T" uniqKey="Brooks J" first="J T" last="Brooks">J T Brooks</name></author><author><name sortKey="Weidle, P J" sort="Weidle, P J" uniqKey="Weidle P" first="P J" last="Weidle">P J Weidle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20659176</idno><idno type="pmid">20659176</idno><idno type="doi">10.1111/j.1468-1293.2010.00873.x</idno><idno type="wicri:Area/PubMed/Corpus">000200</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000200</idno><idno type="wicri:Area/PubMed/Curation">000200</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000200</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.</title><author><name sortKey="Peters, P J" sort="Peters, P J" uniqKey="Peters P" first="P J" last="Peters">P J Peters</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pjpeters@cdc.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA 30333</wicri:regionArea></affiliation></author><author><name sortKey="Stringer, J" sort="Stringer, J" uniqKey="Stringer J" first="J" last="Stringer">J. Stringer</name></author><author><name sortKey="Mcconnell, M S" sort="Mcconnell, M S" uniqKey="Mcconnell M" first="M S" last="Mcconnell">M S Mcconnell</name></author><author><name sortKey="Kiarie, J" sort="Kiarie, J" uniqKey="Kiarie J" first="J" last="Kiarie">J. Kiarie</name></author><author><name sortKey="Ratanasuwan, W" sort="Ratanasuwan, W" uniqKey="Ratanasuwan W" first="W" last="Ratanasuwan">W. Ratanasuwan</name></author><author><name sortKey="Intalapaporn, P" sort="Intalapaporn, P" uniqKey="Intalapaporn P" first="P" last="Intalapaporn">P. Intalapaporn</name></author><author><name sortKey="Potter, D" sort="Potter, D" uniqKey="Potter D" first="D" last="Potter">D. Potter</name></author><author><name sortKey="Mutsotso, W" sort="Mutsotso, W" uniqKey="Mutsotso W" first="W" last="Mutsotso">W. Mutsotso</name></author><author><name sortKey="Zulu, I" sort="Zulu, I" uniqKey="Zulu I" first="I" last="Zulu">I. Zulu</name></author><author><name sortKey="Borkowf, C B" sort="Borkowf, C B" uniqKey="Borkowf C" first="C B" last="Borkowf">C B Borkowf</name></author><author><name sortKey="Bolu, O" sort="Bolu, O" uniqKey="Bolu O" first="O" last="Bolu">O. Bolu</name></author><author><name sortKey="Brooks, J T" sort="Brooks, J T" uniqKey="Brooks J" first="J T" last="Brooks">J T Brooks</name></author><author><name sortKey="Weidle, P J" sort="Weidle, P J" uniqKey="Weidle P" first="P J" last="Weidle">P J Weidle</name></author></analytic><series><title level="j">HIV medicine</title><idno type="eISSN">1468-1293</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Alanine Transaminase (blood)</term><term>Aspartate Aminotransferases (blood)</term><term>CD4 Lymphocyte Count</term><term>Chemical and Drug Induced Liver Injury (blood)</term><term>Chemical and Drug Induced Liver Injury (epidemiology)</term><term>Chemical and Drug Induced Liver Injury (etiology)</term><term>Drug Eruptions (epidemiology)</term><term>Drug Hypersensitivity (epidemiology)</term><term>Drug Hypersensitivity (etiology)</term><term>Drug Therapy, Combination</term><term>Epidemiologic Methods</term><term>Exanthema (chemically induced)</term><term>Exanthema (epidemiology)</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>Humans</term><term>Kenya</term><term>Middle Aged</term><term>Nevirapine (administration & dosage)</term><term>Nevirapine (adverse effects)</term><term>Reverse Transcriptase Inhibitors (administration & dosage)</term><term>Reverse Transcriptase Inhibitors (adverse effects)</term><term>Severity of Illness Index</term><term>Thailand</term><term>Young Adult</term><term>Zambia</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Alanine transaminase (sang)</term><term>Aspartate aminotransferases (sang)</term><term>Association de médicaments</term><term>Exanthème ()</term><term>Exanthème (épidémiologie)</term><term>Femelle</term><term>Humains</term><term>Hypersensibilité médicamenteuse (épidémiologie)</term><term>Hypersensibilité médicamenteuse (étiologie)</term><term>Indice de gravité médicale</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Inhibiteurs de la transcriptase inverse (administration et posologie)</term><term>Inhibiteurs de la transcriptase inverse (effets indésirables)</term><term>Jeune adulte</term><term>Kenya</term><term>Lésions hépatiques dues aux substances (sang)</term><term>Lésions hépatiques dues aux substances (épidémiologie)</term><term>Lésions hépatiques dues aux substances (étiologie)</term><term>Méthodes épidémiologiques</term><term>Numération des lymphocytes CD4</term><term>Névirapine (administration et posologie)</term><term>Névirapine (effets indésirables)</term><term>Thaïlande</term><term>Toxidermies (épidémiologie)</term><term>Zambie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nevirapine</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Nevirapine</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Alanine Transaminase</term><term>Aspartate Aminotransferases</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de la transcriptase inverse</term><term>Névirapine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Exanthema</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de la transcriptase inverse</term><term>Névirapine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term><term>Drug Eruptions</term><term>Drug Hypersensitivity</term><term>Exanthema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term><term>Drug Hypersensitivity</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Alanine transaminase</term><term>Aspartate aminotransferases</term><term>Lésions hépatiques dues aux substances</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Exanthème</term><term>Hypersensibilité médicamenteuse</term><term>Lésions hépatiques dues aux substances</term><term>Toxidermies</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hypersensibilité médicamenteuse</term><term>Lésions hépatiques dues aux substances</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Drug Therapy, Combination</term><term>Epidemiologic Methods</term><term>Female</term><term>Humans</term><term>Kenya</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Thailand</term><term>Young Adult</term><term>Zambia</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Exanthème</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Jeune adulte</term><term>Kenya</term><term>Méthodes épidémiologiques</term><term>Numération des lymphocytes CD4</term><term>Thaïlande</term><term>Zambie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of the study was to determine risk factors for developing severe hepatotoxicity (grade 3 or 4 hepatotoxicity) and rash-associated hepatotoxicity (rash with ≥ grade 2 hepatotoxicity) among women initiating nevirapine-based antiretroviral therapy (ART).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20659176</PMID><DateCreated><Year>2010</Year><Month>10</Month><Day>21</Day></DateCreated><DateCompleted><Year>2011</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-1293</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>HIV medicine</Title><ISOAbbreviation>HIV Med.</ISOAbbreviation></Journal><ArticleTitle>Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.</ArticleTitle><Pagination><MedlinePgn>650-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1468-1293.2010.00873.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to determine risk factors for developing severe hepatotoxicity (grade 3 or 4 hepatotoxicity) and rash-associated hepatotoxicity (rash with ≥ grade 2 hepatotoxicity) among women initiating nevirapine-based antiretroviral therapy (ART).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Non-Nucleoside Reverse Transcriptase Inhibitor Response Study was a prospective cohort study carried out in Zambia, Thailand and Kenya. Between May 2005 and January 2007, we enrolled antiretroviral-naïve HIV-infected women initiating nevirapine-based ART. At enrollment and at weeks 2, 4, 8, 16 and 24, participants had serum alanine transferase (ALT) and aspartate transaminase (AST) measured and were evaluated clinically for hepatitis and rash.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women. After initiating nevirapine-based ART, severe hepatotoxicity occurred in 41 (5%) women and rash-associated hepatotoxicity occurred in 27 (3%) women. In a multivariate logistic regression model, severe hepatotoxicity and rash-associated hepatotoxicity were both associated with baseline abnormal (≥ grade 1) ALT or AST results, but not with a baseline CD4 cell count ≥250 cells/μL. Three participants (0.4%) died with symptoms suggestive of fatal hepatotoxicity; all three women had baseline CD4 count <100 cells/μL and were receiving anti-tuberculosis therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among women taking nevirapine-based ART, severe hepatotoxicity and rash-associated hepatotoxicity were predicted by abnormal baseline ALT or AST results, but not by a CD4 count ≥250 cells/μL. In resource-limited settings where transaminase testing is available, testing should focus on early time-points and on women with abnormal baseline ALT or AST results.</AbstractText><CopyrightInformation>© 2010 British HIV Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pjpeters@cdc.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stringer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McConnell</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Kiarie</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ratanasuwan</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Intalapaporn</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mutsotso</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zulu</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Borkowf</LastName><ForeName>C B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Weidle</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U62/CCU024526</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U62/CCU12354</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>HIV Med</MedlineTA><NlmUniqueID>100897392</NlmUniqueID><ISSNLinking>1464-2662</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>99DK7FVK1H</RegistryNumber><NameOfSubstance UI="D019829">Nevirapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.6.1.1</RegistryNumber><NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.6.1.2</RegistryNumber><NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000410" MajorTopicYN="N">Alanine Transaminase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001219" MajorTopicYN="N">Aspartate Aminotransferases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003875" MajorTopicYN="N">Drug Eruptions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="N">Exanthema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007630" MajorTopicYN="N">Kenya</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019829" MajorTopicYN="N">Nevirapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015024" MajorTopicYN="N">Zambia</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20659176</ArticleId><ArticleId IdType="pii">HIV873</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1293.2010.00873.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000200 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000200 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20659176
|texte= Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20659176" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |